simtuzumab (GS 6624) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
simtuzumab (GS 6624) / Gilead
NCT01242709: Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Not yet recruiting
2
54
US
AB0024
Arresto Biosciences, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
12/11
12/13

Download Options